Suppr超能文献

设计的螺环缩酮蛋白调节。

Designed Spiroketal Protein Modulation.

机构信息

Laboratory of Chemical Biology and Institute for Complex Molecular Systems (ICMS), Department of Biomedical Engineering, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands.

Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747AG, Groningen, The Netherlands.

出版信息

Angew Chem Int Ed Engl. 2017 May 8;56(20):5480-5484. doi: 10.1002/anie.201612504. Epub 2017 Apr 13.

Abstract

Spiroketals are structural motifs found in many biologically active natural products, which has stimulated considerable efforts toward their synthesis and interest in their use as drug lead compounds. Despite this, the use of spiroketals, and especially bisbenzanulated spiroketals, in a structure-based drug discovery setting has not been convincingly demonstrated. Herein, we report the rational design of a bisbenzannulated spiroketal that potently binds to the retinoid X receptor (RXR) thereby inducing partial co-activator recruitment. We solved the crystal structure of the spiroketal-hRXRα-TIF2 ternary complex, and identified a canonical allosteric mechanism as a possible explanation for the partial agonist behavior of our spiroketal. Our co-crystal structure, the first of a designed spiroketal-protein complex, suggests that spiroketals can be designed to selectively target other nuclear receptor subtypes.

摘要

螺环缩酮是许多具有生物活性的天然产物中的结构基序,这激发了人们对其合成的大量研究,并使其作为药物先导化合物引起了人们的兴趣。尽管如此,在基于结构的药物发现环境中,螺环缩酮,特别是双苯并螺环缩酮的使用尚未得到令人信服的证明。在此,我们报告了一种双苯并螺环缩酮的合理设计,该螺环缩酮能够强烈结合视黄醇 X 受体(RXR),从而诱导部分共激活剂募集。我们解决了螺环缩酮-hRXRα-TIF2 三元复合物的晶体结构,并确定了一种典型的变构机制,这可能是我们的螺环缩酮呈现部分激动剂行为的原因。我们的共晶结构是第一个设计的螺环缩酮-蛋白复合物,表明可以设计螺环缩酮以选择性地针对其他核受体亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78b0/5435924/fe9776bcc93f/ANIE-56-5480-g004.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验